Catalent
CTLT

$58.68

0.39%

Market Cap: 10.6B

About: Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Employees: 17,219

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 7 analysts

0

News positive %

of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

29.77% more ownership

Funds ownership: 109.82% [Q4 2023] → 139.59% (+29.77%) [Q1 2024]

14% more call options, than puts

Call options by funds: $52.8M | Put options by funds: $46.4M

13% more funds holding in top 10

Funds holding in top 10: 8 [Q4 2023] → 9 (+1) [Q1 2024]

10% more capital invested

Capital invested by funds: $8.91B [Q4 2023] → $9.82B (+$912M) [Q1 2024]

2% more funds holding

Funds holding: 413 [Q4 2023] → 420 (+7) [Q1 2024]

8% more first-time investments, than exits

New positions opened: 94 | Existing positions closed: 87

14% less repeat investments, than reductions

Existing positions increased: 132 | Existing positions reduced: 153

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$63

7%

upside

Avg. target

$63

8%

upside

High target

$64

8%

upside

7 analyst ratings

0 positive

0%

7 neutral

100%

0 negative

0%

RBC Capital Sean Dodge	8%upside $63.5	Sector Perform Reiterated	11 Jul 2024
Barclays Luke Sergott	7%upside $63	Equal-Weight Maintained	28 Jun 2024
Stephens & Co. Jacob Johnson	8%upside $63.5	Equal-Weight Reiterated	4 Apr 2024
RBC Capital Sean Dodge	8%upside $63.5	Sector Perform Reiterated	20 Feb 2024
RBC Capital Sean Dodge	8%upside $63.5	Sector Perform Downgraded	6 Feb 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about CTLT published over the past 30 days

Zacks Investment Research

UTHR vs. CTLT: Which Stock Is the Better Value Option?

Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?

UTHR vs. CTLT: Which Stock Is the Better Value Option?

Zacks Investment Research

Catalent (CTLT) Expands Its Facility Capabilities in Germany

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.

Catalent (CTLT) Expands Its Facility Capabilities in Germany

Zacks Investment Research

UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two stocks offers value investors a better bang for their buck right now?

UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?

Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany. The Schorndorf site, Catalent's flagship European facility, provides comprehensive clinical supply services, including packaging, storage and distribution. The expansion increases the site's footprint by 32,000 square feet (3,000 square meters.

Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany

Zacks Investment Research

UTHR or CTLT: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?

UTHR or CTLT: Which Is the Better Value Stock Right Now?

Investors Business Daily

7 Stocks' Profit Growth Will Blow Past Nvidia's This Quarter

Nvidia's profit is growing fast, but not the fastest in the S&P 500. Not by a long shot, say stock analysts.

7 Stocks' Profit Growth Will Blow Past Nvidia's This Quarter

Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty

Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.

Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty

Zacks Investment Research

Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?

Catalent stockholders approve deal with Novo Holdings

Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.

Catalent stockholders approve deal with Novo Holdings

Catalent Stockholders Approve Transaction with Novo Holdings

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”). “Today's outcome represents.

Catalent Stockholders Approve Transaction with Novo Holdings

See News Rankings